August 10, 2020 by Brian Ross
a Nielsen company, Brian Ross is president of Precima
August 10, 2020, Opinion
For drug, food and mass retailers, assortment management is a perennial challenge in the best of times, one that requires discipline and sound practices. The COVID-19 pandemic elevated the stress placed on assortment management to a new level. Demand signals were shattered by unpredictable shopper behavior across categories. Massive disruptions meant that supply chains struggled
August 10, 2020 by Chain Drug Review
Kathleen Wilson-Thompson, Latriece Watkins, WE
August 10, 2020, News
NEW YORK — The killing of George Floyd by police in Minneapolis has sparked a national conversation on racial injustice and economic inequality that could provide an opportunity for real change, including in corporate America. “This awakening light has had all of us across corporate America having this conversation,” Walgreens Boots Alliance executive vice president
August 10, 2020 by David Pinto
Chain Drug Marketing Association (CDMA), Jim Devine
August 10, 2020, Opinion
To those who know Jim Devine, no explanation is necessary; to those who don’t, no explanation is possible. That bromide, used with varying degrees of effectiveness over the decades, has never been put to better use than to describe the chain drug veteran whose diligence, dedication and hard work has transformed chain drug retailing as
August 10, 2020 by Jeffrey Woldt
Stefano Pessina, Walgreens Boots Alliance (WBA)
August 10, 2020, Opinion
Stefano Pessina’s decision to step down as Walgreens Boots Alliance’s chief executive officer has triggered speculation in the retail pharmacy and drug wholesaling sectors about the change, its timing and what it might portend for the company. Those who have followed WBA since its formation and, prior to that, Alliance Boots, which Pessina merged with
July 31, 2020 by Matt Katz, Nick Kramer and Chris Ventry
Chris Ventry, Matt Katz, Matt Kramer, SSA & Co.
July 27, 2020, Opinion, Technology
A consistent theme across industries is that the lockdown accelerated digital transformation, opening up numerous short-term and strategic benefit drivers. But when economic uncertainty makes it necessary to minimize investment, the challenge is knowing which bets to make and which levers to pull now. For chain drug stores, we see this “Sprint with Digital” manifesting
July 30, 2020 by Duane Harrington and Leslie Lotano-Saba
AArete, COVID-19, Duane Harrington, Leslie Lotano-Saba
July 27, 2020, Opinion
Among the many promising advances in medical legislation over the past several decades has been the passage of “provider status” laws for pharmacists in many states. While the specifics vary from state to state, the general intent behind this legislation is to give patients increased access to some of the oft-underutilized services that pharmacists can
July 30, 2020 by Brian Owens
Brian Owens is senior vice president of Retail Insights at Kantar.
July 27, 2020, Opinion
With U.S. health care spending expected to rise above $4.2 trillion at a CAGR of 5% in 2019-2023, the level of engagement for consumer, patient and omnicommerce digital health solutions has exploded. Tech giants such as Microsoft and Best Buy are investing in digital health technology to improve consumer health experiences. Retailer capital investments in
July 30, 2020 by Jill Regan
Jill Regan is director of relationship management at LexisNexis Solutions — Health Care
July 27, 2020, Opinion
2020 will forever be remembered for the devastating impact of the COVID-19 pandemic. On a personal level, relationships and daily routines changed to accommodate new concerns and norms of daily lives. On a professional level, the role of pharmacists as a trusted health care professional came again into focus as the unexpected demands of COVID-19
July 29, 2020 by Alan Arville, Chris Smith and John Linehan
Epstein Becker Green, Medicaid managed care organizations (MCOs), Medicaid programs
July 27, 2020, Opinion
In order to address rising drug prices, state Medicaid programs have been searching for new and creative means to better control their pharmacy benefit and mitigate the budgetary impact. This has led to an interesting trend reversal in how state Medicaid programs are structuring their management and coverage of pharmacy benefits. Since the passage of
July 28, 2020 by Chain Drug Review
Dr. Reddy's Laboratories, Vanessa Brill
July 27, 2020, Pharmacy
PRINCETON, N.J. — When the COVID-19 pandemic hit, the generic drug industry faced many challenges, says Vanessa Brill, vice president and regional general counsel for the Americas at Dr. Reddy’s Laboratories. For Dr. Reddy’s, the challenges included finding ways to continue to produce drugs at manufacturing facilities that had to operate at decreased capacity out
July 28, 2020 by Lari Harding
COVID-19, Grocery pharmacies, Lari Harding is vice president of client development at Inmar Intelligence.
July 27, 2020, Opinion
Health care needs changes. We have been talking about them for years. We all know what they are — better care, lower costs and more accessibility. I find myself thinking that necessity is the mother of invention — or at least the accelerator of change. COVID-19 has spurred an acceleration of innovation and creativity that
July 28, 2020 by Dan Leonard
COVID-19, Dan Leonard is president and chief executive officer of the National Pharmaceutical Council.
July 27, 2020, Opinion
As the country tentatively prepares to return to school and the office this fall, there seems to be little certainty except that the coronavirus threat will be with us for a long while. Social distancing and economic uncertainty will remain a part of everyday life. The pandemic has highlighted the fragility of our social safety
July 28, 2020 by Chain Drug Review
Heyward Donigan, Rite Aid
July 27, 2020, News
CAMP HILL, Pa. — As part of its ongoing efforts to closely manage and reduce costs, Rite Aid Corp. has eliminated 254 corporate office positions across its retail pharmacy and pharmacy services segments, the company reported in the release of its first quarter earnings. Rite Aid has also taken steps to reduce other expenses, such
July 27, 2020 by Stephen Ubl
Steve Ubl is president and chief executive officer of Pharmaceutical Research and Manufacturers of America (PhRMA).
July 27, 2020, Opinion
Long after the sun goes down, the work of America’s biopharmaceutical companies continues deep into the night. Researchers and scientists labor around the clock, developing new ways to diagnose, treat and cure COVID-19. While they do, so many of the people they’re working to help stare at the ceiling and wonder how they will afford